Momentum builds for neglected diseases drug discovery

Dr Charlie Mowbray, DNDi, Dr David Waterson, MMV, and Dr Takushi Kaneko, TB Alliance

Research led by Product Development Partnerships (PDPs) such as MMV, Drugs for Neglected Diseases initiative (DNDi) and the Global Alliance for Tuberculosis Drug Development (TB Alliance) is starting to pay off. Participants at the 2012 International Symposium on Medicinal Chemistry (the world’s largest medicinal chemistry conference), heard how research to identify promising new molecules for diseases like malaria, visceral leishmaniasis and TB is making real progress.

What is the role of PDPs in drug discovery for neglected diseases?

What are the main challenges drug discovery poses?

What are the main approaches to discover new drugs for malaria?